RC
BMY.RT

RegentAtlantic Capital’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

RegentAtlantic Capital’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-30,393
Closed -$21K – 561
2020
Q4 		$21K Buy
30,393
+573
+2% +$1.22K ﹤0.01% 500
2020
Q3 		$67K Sell
29,820
-256
-0.9% -$731 ﹤0.01% 480
2020
Q2 		$108K Buy
30,076
+2,280
+8% +$8.23K 0.01% 463
2020
Q1 		$106K Buy
27,796
+122
+0.4% +$402 0.01% 404
2019
Q4 		$83K Buy
+27,674
New +$72K 0.01% 458

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

RegentAtlantic Capital's BMY.RT Position: Q1 2021 in Review

RegentAtlantic Capital sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 30,393 shares — an estimated $21K sold.

RegentAtlantic Capital first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $108K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • RegentAtlantic Capital reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • RegentAtlantic Capital sold 30,393 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $21K.
  • RegentAtlantic Capital first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • RegentAtlantic Capital's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $108K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on RegentAtlantic Capital's 13F filing for Q1 2021, filed 29 Apr 2021.